{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:14:34Z","timestamp":1793938474815,"version":"4.8.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.heliyon.2022.e09503","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T13:23:42Z","timestamp":1653053022000},"page":"e09503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Dapagliflozin induces vasodilation in resistance-size mesenteric arteries by stimulating smooth muscle cell KV7 ion channels"],"prefix":"10.1016","volume":"8","author":[{"given":"Ahasanul","family":"Hasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreelakshmi N.","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Zerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6897-2901","authenticated-orcid":false,"given":"Raquibul","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.heliyon.2022.e09503_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41371-019-0268-x","article-title":"Hypertension and type 2 diabetes: lights and shadows about causality","volume":"34","author":"Colussi","year":"2020","journal-title":"J.\u00a0Hum. Hypertens."},{"issue":"5","key":"10.1016\/j.heliyon.2022.e09503_bib2","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/01.HYP.0000125726.92964.ab","article-title":"Adverse prognostic significance of new diabetes in treated hypertensive subjects","volume":"43","author":"Verdecchia","year":"2004","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.heliyon.2022.e09503_bib3","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/hr.2017.67","article-title":"Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese","volume":"40","author":"Tatsumi","year":"2017","journal-title":"Hypertens. Res."},{"issue":"5","key":"10.1016\/j.heliyon.2022.e09503_bib4","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/ajh\/hpy025","article-title":"Diabetes and hypertension: clinical update","volume":"31","author":"Khangura","year":"2018","journal-title":"Am. J. Hypertens."},{"issue":"5","key":"10.1016\/j.heliyon.2022.e09503_bib5","article-title":"Effects of sodium\/glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials","volume":"10","author":"Teo","year":"2021","journal-title":"J.\u00a0Am. Heart Assoc."},{"issue":"6","key":"10.1016\/j.heliyon.2022.e09503_bib6","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose Co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"issue":"2","key":"10.1016\/j.heliyon.2022.e09503_bib7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur. Heart J."},{"issue":"21","key":"10.1016\/j.heliyon.2022.e09503_bib8","first-page":"2099","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"3","key":"10.1016\/j.heliyon.2022.e09503_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","article-title":"Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"4","author":"Weber","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"19","key":"10.1016\/j.heliyon.2022.e09503_bib10","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur. Heart J."},{"issue":"22","key":"10.1016\/j.heliyon.2022.e09503_bib11","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"3","key":"10.1016\/j.heliyon.2022.e09503_bib12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3810\/pgm.2013.05.2667","article-title":"Effects of dapagliflozin on cardiovascular risk factors","volume":"125","author":"Ptaszynska","year":"2013","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.heliyon.2022.e09503_bib13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.lfs.2018.01.032","article-title":"The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels","volume":"197","author":"Li","year":"2018","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.heliyon.2022.e09503_bib14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1161\/HYPERTENSIONAHA.120.16466","article-title":"Mechanisms of SGLT2 (Sodium-Glucose transporter type 2) inhibition-induced relaxation in arteries from human visceral adipose tissue","volume":"77","author":"De Stefano","year":"2021","journal-title":"Hypertension"},{"issue":"19","key":"10.1016\/j.heliyon.2022.e09503_bib15","doi-asserted-by":"crossref","first-page":"10842","DOI":"10.3390\/ijms221910842","article-title":"Empagliflozin relaxes resistance mesenteric arteries by stimulating multiple smooth muscle cell voltage-gated K+ (KV) channels","volume":"22","author":"Hasan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2022.e09503_bib16","doi-asserted-by":"crossref","first-page":"115153","DOI":"10.1016\/j.taap.2020.115153","article-title":"Empagliflozin dilates the rabbit aorta by activating PKG and\u00a0voltage-dependent K(+) channels","volume":"403","author":"Seo","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"1","key":"10.1016\/j.heliyon.2022.e09503_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12967-019-1881-8","article-title":"Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation","volume":"17","author":"Sayour","year":"2019","journal-title":"J.\u00a0Transl. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2022.e09503_bib18","doi-asserted-by":"crossref","first-page":"14659","DOI":"10.1038\/s41598-020-71599-2","article-title":"Canagliflozin ameliorates renal oxidative stress and inflammation by stimulating AMPK-Akt-eNOS pathway in the isoprenaline-induced oxidative stress model","volume":"10","author":"Hasan","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2022.e09503_bib19","doi-asserted-by":"crossref","first-page":"113677","DOI":"10.1016\/j.bcp.2019.113677","article-title":"Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats","volume":"170","author":"Arag\u00f3n-Herrera","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.heliyon.2022.e09503_bib20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12933-018-0749-1","article-title":"Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice","volume":"17","author":"Nasiri-Ansari","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.heliyon.2022.e09503_bib21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12933-018-0745-5","article-title":"Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors","volume":"17","author":"Lahnwong","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.heliyon.2022.e09503_bib22","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","article-title":"The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats","volume":"13","author":"Steven","year":"2017","journal-title":"Redox Biol."},{"issue":"2","key":"10.1016\/j.heliyon.2022.e09503_bib23","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","article-title":"The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE (-\/-) mice fed a western diet","volume":"60","author":"Han","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.heliyon.2022.e09503_bib24","article-title":"Correction: intravascular flow stimulates PKD2 (polycystin-2) channels in endothelial cells to reduce blood pressure","volume":"9","author":"MacKay","year":"2020","journal-title":"Elife"},{"issue":"52","key":"10.1016\/j.heliyon.2022.e09503_bib25","doi-asserted-by":"crossref","first-page":"27095","DOI":"10.1073\/pnas.1917264116","article-title":"SUMO1 modification of PKD2 channels regulates arterial contractility","volume":"116","author":"Hasan","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.heliyon.2022.e09503_bib26","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.42628","article-title":"Arterial smooth muscle cell PKD2 (TRPP1) channels regulate systemic blood pressure","volume":"7","author":"Bulley","year":"2018","journal-title":"Elife"},{"issue":"390","key":"10.1016\/j.heliyon.2022.e09503_bib27","doi-asserted-by":"crossref","first-page":"ra83","DOI":"10.1126\/scisignal.aac5128","article-title":"Intravascular pressure enhances the abundance of functional Kv1.5 channels at the surface of arterial smooth muscle cells","volume":"8","author":"Kidd","year":"2015","journal-title":"Sci. Signal."},{"issue":"1","key":"10.1016\/j.heliyon.2022.e09503_bib28","doi-asserted-by":"crossref","first-page":"14459","DOI":"10.1038\/s41598-020-71449-1","article-title":"Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways","volume":"10","author":"Hasan","year":"2020","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.heliyon.2022.e09503_bib29","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1124\/pr.110.002907","article-title":"cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action","volume":"62","author":"Francis","year":"2010","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"10.1016\/j.heliyon.2022.e09503_bib30","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/pr.111.004770","article-title":"Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn","volume":"64","author":"Majed","year":"2012","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.heliyon.2022.e09503_bib31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/j.2040-4603.2017.tb00747.x","article-title":"Smooth muscle ion channels and regulation of vascular tone in resistance arteries and arterioles","volume":"7","author":"Tykocki","year":"2017","journal-title":"Compr. Physiol."},{"issue":"1","key":"10.1016\/j.heliyon.2022.e09503_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/micc.12421","article-title":"K(V) channels and the regulation of vascular smooth muscle tone","volume":"25","author":"Jackson","year":"2018","journal-title":"Microcirculation"},{"issue":"1","key":"10.1016\/j.heliyon.2022.e09503_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/micc.12418","article-title":"K(V) channel trafficking and control of vascular tone","volume":"25","author":"Hasan","year":"2018","journal-title":"Microcirculation"},{"issue":"1","key":"10.1016\/j.heliyon.2022.e09503_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cardiores.2003.12.026","article-title":"Pharmacology of cardiac potassium channels","volume":"62","author":"Tamargo","year":"2004","journal-title":"Cardiovasc. Res."},{"issue":"3","key":"10.1016\/j.heliyon.2022.e09503_bib35","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1124\/jpet.106.101162","article-title":"Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current","volume":"317","author":"Lagrutta","year":"2006","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"issue":"3","key":"10.1016\/j.heliyon.2022.e09503_bib36","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1124\/jpet.105.092197","article-title":"In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide","volume":"315","author":"Stump","year":"2005","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"issue":"4","key":"10.1016\/j.heliyon.2022.e09503_bib37","doi-asserted-by":"crossref","first-page":"C859","DOI":"10.1152\/ajpcell.2001.280.4.C859","article-title":"KCNQ4 channels expressed in mammalian cells: functional characteristics and pharmacology","volume":"280","author":"S\u00f8gaard","year":"2001","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"2","key":"10.1016\/j.heliyon.2022.e09503_bib38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1540\/jsmr.44.65","article-title":"Physiological roles of K+ channels in vascular smooth muscle cells","volume":"44","author":"Ko","year":"2008","journal-title":"J.\u00a0Smooth Muscle Res."},{"issue":"5","key":"10.1016\/j.heliyon.2022.e09503_bib39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1085\/jgp.201411259","article-title":"Paxilline inhibits BK channels by an almost exclusively\u00a0closed-channel block mechanism","volume":"144","author":"Zhou","year":"2014","journal-title":"J.\u00a0Gen. Physiol."},{"issue":"3","key":"10.1016\/j.heliyon.2022.e09503_bib40","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1211\/0022357022755","article-title":"Blocking actions of glibenclamide on ATP-sensitive K+ channels in pig urethral myocytes","volume":"56","author":"Teramoto","year":"2004","journal-title":"J.\u00a0Pharm. Pharmacol."},{"issue":"2","key":"10.1016\/j.heliyon.2022.e09503_bib41","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/cvr\/cvy295","article-title":"Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review\u00a0of\u00a0data from preclinical studies","volume":"115","author":"Chin","year":"2019","journal-title":"Cardiovasc. Res."},{"issue":"3","key":"10.1016\/j.heliyon.2022.e09503_bib42","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.heliyon.2022.e09503_bib43","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes. Metabol."},{"issue":"1","key":"10.1016\/j.heliyon.2022.e09503_bib44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12933-019-0839-8","article-title":"How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial","volume":"18","author":"Bosch","year":"2019","journal-title":"Cardiovasc. Diabetol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844022007915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844022007915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T04:35:38Z","timestamp":1767760538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844022007915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S2405844022007915"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2022.e09503","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dapagliflozin induces vasodilation in resistance-size mesenteric arteries by stimulating smooth muscle cell KV7 ion channels","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2022.e09503","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e09503"}}